[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"healthy-individuals-with-no-cardiopulmonary-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:healthy-individuals-with-no-cardiopulmonary-disease":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":5},"100484183","risk-and-resilience-in-pulmonary-arterial-hypertension-and-genetically-susceptible-individuals-100484183",false,"NCT05584722","Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals","RARE-PAH","Inclusion Criteria:\n\n* Children and Adults, aged 15 - 80\n* Diagnosed with idiopathic or heritable, pulmonary arterial hypertension (PAH), defined according to standard criteria\n* Unaffected Mutation Carriers: Healthy participants with a known BMPR2 gene mutation and normal pulmonary pressure and RV function on echo\n* Healthy Controls: Healthy individuals without cardiopulmonary disease.\n* WHO functional class I-III\n* Stable PAH-specific medication regimen for three months prior to enrollment. Subjects with only a single diuretic adjustment in the prior three months will be included. Adjustments in IV prostacyclin for side effect management are allowed.\n\nExclusion Criteria:\n\n* Prohibited from normal activity due to wheelchair bound status, bed bound status, reliance on a cane\u002Fwalker, activity-limiting angina, activity-limiting osteoarthritis, or other condition that limits activity.\n* Pregnancy\n* Diagnosis of PAH etiology other than idiopathic, heritable\n* Functional class IV heart failure\n* Requirement of \\> 2 diuretic adjustment in the prior three months.","ALL","15 Years","80 Years",{"count":20,"type":21},150,"ESTIMATED","OBSERVATIONAL","Pulmonary arterial hypertension (PAH) is a severe disease with a delayed diagnosis and markedly elevated mortality. High-risk populations, such as those with known genetic defects, provide a unique opportunity to determine the features of susceptibility and resilience to PAH. This proposal will fundamentally overturn the prevailing understanding of PAH by creating molecularly-driven signatures of susceptibility and resilience, provide novel insight into disease severity, and potentially identify new therapeutic targets.\n\nFunding Source - FDA OOPD",[25,26,27,28],"Idiopathic Pulmonary Arterial Hypertension","Heritable Pulmonary Arterial Hypertension","Unaffected Mutation Carriers: Healthy Participants With a Known BMPR2 Gene Mutation and Normal Pulmonary Pressure and RV Function on Echo","Healthy Individuals With no Cardiopulmonary Disease",[30],"pulmonary hypertension","RECRUITING","2026-03-09",{"date":34,"type":35},"2026-03-10","ACTUAL",{"date":37,"type":35},"2022-11-01",{"date":39,"type":21},"2026-08-31",{"name":41,"class":42},"Vanderbilt University Medical Center","OTHER"]